Tags : ADCT-402

Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker

Shots: ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) The focus of the collaboration is to develop innovative cancer therapies, highlighting the potential of Freenome’s platform providing tumor and immune signatures for hematological […]Read More